SCHEMBL4714110

SCHEMBL4714110

O=c1ccc2c(ccn2Cc2ccc(Cl)cc2)n1-c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
HTT P42858 2/20 0.44
ALDH1A1 P00352 2/20 0.43
POLB P06746 2/20 0.43
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPSR1 Q6W5P4 1/20 0.41
VEGFA P15692 2/20 0.41
EGLN1 Q9GZT9 2/20 0.41
MAPK8 P45983 3/20 0.40
MAPK9 P45984 1/20 0.40
MAPT P10636 2/20 0.40
THRB P10828 1/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
BRD4 O60885 1/20 0.39
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4713845 0.91 BRD4 (0.46) HTTALDH1A1KDM4ESMN1; SMN2MAPK8
SCHEMBL5124227 0.88 SMN1; SMN2 (0.43) LMNAHTTALDH1A1KDM4ESMN1; SMN2
SCHEMBL4715873 0.88 TP53 (0.46) LMNAHTTALDH1A1POLBKDM4E
SCHEMBL4715863 0.87 CYP3A4 (0.46) HTTALDH1A1POLBKDM4ESMN1; SMN2
SCHEMBL4716315 0.87 ALDH1A1 (0.47) LMNAHTTALDH1A1POLBKDM4E
SCHEMBL4716165 0.86 PIK3CD (0.40) LMNAHTTPOLBMAPK8MAPK9
SCHEMBL5113137 0.85 HTR6 (0.44) LMNAHTTALDH1A1KDM4ESMN1; SMN2
SCHEMBL4761608 0.84 MAPT (0.36) LMNAHTTALDH1A1POLBMAPT
SCHEMBL4716129 0.84 CYP11B1 (0.41) LMNAHTTALDH1A1POLBKDM4E
SCHEMBL4711879 0.83 MEN1 (0.41) LMNAHTTMAPK8MAPK9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US claimed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US claimed
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed
EP-1549648-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS Celltech R & D Limited (GB) 2005-07-06 EP disclosed
WO-2004031188-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS CELLTECH R & D LIMITED (GB) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 LMNA 4269/4885HTT 4051/4885ALDH1A1 3407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.